Literature DB >> 22572504

A case of reversible dilated cardiomyopathy due to acromegaly with partial empty sella.

Shrenik R Doshi1, Sachin B Punatar.   

Abstract

Acromegaly has several cardiovascular manifestations of which cardiomyopathy (CMP) and hypertension (HTN) are important and contribute to the increased mortality associated with the disease. Both these manifestations are reversible with treatment. However, very advanced CMP with severe systolic dysfunction has low likelihood of reversal. The reversibility is higher in young population and decreases as age advances. Also, the time required for these manifestations to resolve is about 1 year. Here, we describe a case in which HTN and advanced heart failure resolved in an aged patient within a very short span of 2 months from the time of presentation.
Copyright © 2012 Cardiological Society of India. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22572504      PMCID: PMC3860701          DOI: 10.1016/S0019-4832(12)60065-0

Source DB:  PubMed          Journal:  Indian Heart J        ISSN: 0019-4832


  2 in total

1.  Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance.

Authors:  Rosario Pivonello; Maurizio Galderisi; Renata S Auriemma; Maria Cristina De Martino; Mariano Galdiero; Antonio Ciccarelli; Arcangelo D'Errico; Ione Kourides; Pia Burman; Gaetano Lombardi; Annamaria Colao
Journal:  J Clin Endocrinol Metab       Date:  2006-11-14       Impact factor: 5.958

2.  Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly.

Authors:  A Colao; A Cuocolo; P Marzullo; E Nicolai; D Ferone; L Florimonte; M Salvatore; G Lombardi
Journal:  J Clin Endocrinol Metab       Date:  1999-01       Impact factor: 5.958

  2 in total
  1 in total

1.  Acromegaly-induced cardiomyopathy with dobutamine-induced outflow tract obstruction.

Authors:  Mahmoud A Abdelsalam; Todd B Nippoldt; Jeffrey B Geske
Journal:  BMJ Case Rep       Date:  2016-03-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.